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Abstract
Background: In Alzheimer’s disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and
plaques, a process which is associated with neuronal degeneration, memory loss, and cognitive decline. One
therapeutic strategy is to decrease the production of potentially toxic beta-amyloid species by the use of inhibitors
or modulators of the enzymes that produce beta-amyloid from amyloid precursor protein (APP). The failures of
several such drug candidates by lack of effect or undesired side-effects underscore the importance to monitor the
drug effects in the brain on a molecular level. Here we evaluate if peptidomic analysis in cerebrospinal fluid (CSF)
can be used for this purpose.
Methods: Fifteen human healthy volunteers, divided into three groups, received a single dose of placebo or either
140 mg or 280 mg of the γ-secretase inhibitor semagacestat (LY450139). Endogenous peptides in CSF, sampled
prior to administration of the drug and at six subsequent time points, were analyzed by liquid chromatography
coupled to mass spectrometry, using isobaric labeling based on the tandem mass tag approach for relative
quantification.
Results: Out of 302 reproducibly detected peptides, 11 were affected by the treatment. Among these, one was
derived from APP and one from amyloid precursor-like protein 1. Nine peptides were derived from proteins that
may not be γ-secretase substrates per se, but that are regulated in a γ-secretase-dependent manner.
Conclusions: These results indicate that a CSF peptidomic approach may be a valuable tool both to verify target
engagement and to identify other pharmacodynamic effects of the drug. Data are available via ProteomeXchange
with identifier PXD003075.
Trial registration: NCT00765115, registered 30/09/2008.
Background
Alzheimer’s disease (AD) is the most common form of de-
mentia, affecting an increasing number of people worldwide
and presenting a severe social and economic burden. A cen-
tral aspect of the AD pathology is the formation of plaques in
the brain, consisting of aggregated amyloid-β (Aβ) peptides
[1]. A variety of Aβ peptides are produced by enzymatic
cleavage of the amyloid precursor protein (APP) by β-
secretase (BACE) and γ-secretase, of which the 42 amino acid
long Aβ peptide (Aβ42) is most prone to aggregation [2] and
has been proposed to be the driving force in the disease [3, 4].
Several treatment strategies currently under investigation
target the production or clearance of Aβ, e.g., immunother-
apy with anti-Aβ antibodies, and treatment with γ-secretase
inhibitors (GSIs) and BACE inhibitors [5, 6]. While some of
these strategies have yielded positive results in preclinical
studies, they have so far been unsuccessful in slowing cogni-
tive decline in humanAD subjects [7]. The GSI semagacestat
showed promising effects in animal models [8] and also de-
creased the amount of newly produced Aβ in humans [9],
but a phase III clinical trial failed to reach clinical endpoints
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and the drug turned out to have clinically significant adverse
cognitive effects [10, 11].
Monitoring drug treatment effects on a molecular level
is important to determine if a drug affects the intended
target protein, but also to examine if other proteins are
affected. The aim of this study was to test if an unbiased
peptidomic approach can be used for this purpose. Pre-
vious studies have demonstrated the presence of a large
number of endogenous peptides in cerebrospinal fluid
(CSF) [12–16]. While the majority of CSF proteomic
studies to date follow the strategy of analyzing proteins
digested with trypsin, endogenous peptides – the CSF
peptidome – may also be a valuable source of biomarkers,
particularly for studying biological events involving pro-
teolytic processing. Recently, we reported on a method for
multiplex quantitative peptidomic analysis in CSF, based
on isobaric labeling using the tandem mass tag (TMT) ap-
proach [17] combined with liquid chromatography-mass
spectrometry (LC-MS) [18].
In the current study we aim, by analyzing CSF from
healthy subjects treated with the GSI semagacestat, to
test if this approach can be used to detect drug treat-
ment effects on proteolytic processing in the brain, to
identify substrates affected by the drug and to quantify
those effects. This is, to our knowledge, the first study
that explores an endopeptidomic approach for the dis-
covery of pharmacodynamic biomarkers in human CSF.
Methods
Experimental design and statistical rationale
CSF from a previous study was used, in which 20 healthy
human volunteers received either placebo or 100 mg,
140 mg, or 280 mg semagacestat, and CSF was sampled
every hour via an indwelling catheter in the lumbar thecal
sac for 36 h following oral drug administration [9, 19]
(https://clinicaltrials.gov/ct2/show/NCT00765115). The
study was approved by the Washington University Human
Studies Committee, and was performed in compliance
with the Helsinki Declaration. All participants and care-
givers gave written informed consent. In the current study,
CSF from the placebo group, the 140 mg group and the
280 mg group, sampled at 0 h, 3 h, 9 h, 12 h, 18 h, and
36 h were used (Table 1). The time points were selected
based on the results in previous studies [9, 19], where a
maximum Aβ inhibitory effect was seen between 9 and
12 h, and the values returned to approximately the same
as for the placebo group at 36 h.
The experimental design is shown in Fig. 1. Neat CSF
sampled at six consecutive time points before and after
drug administration was labeled with isobaric TMT
reagents, using a protocol recently developed in our
laboratory [18]. Briefly, 100 μl aliquots of neat CSF from
each participant and time point was subjected to reduc-
tion and carbamidomethylation of cysteines followed by
isobaric labelling using TMT 6-plex amino-reactive re-
agents (Thermo Scientific). The CSF sample corre-
sponding to time point zero from each participant was
labeled with TMT-126, the next time point from the same
participant with TMT-127, and so on (Table 1). The six
samples from each participant were then combined into
one TMT 6-plex set. The CSF samples from one partici-
pant were then combined into one TMT6-plex set. The
TMT6-plex sets were subjected to ultrafiltration using
30 kDa molecular weight cut-off filters (Vivacon 2 HY,
Sartorius Stedim). The flow-through, containing the en-
dogenous peptide fraction, was desalted on C18 car-
tridges (SEP-PAK, Waters), lyophilized and stored at
-80 °C pending analysis. The CSF samples were analyzed
by LC-MS in two technical replicates to improve the iden-
tification and quantification overlap between study
participants.
Table 1 Distribution of the CSF samples within the TMT
6-plex sets
TMT label 126 127 128 129 130 131
Time point 0 h 3 h 9 h 12 h 18 h 36 h
The CSF samples were labeled with TMT 6-plex reagents according to the
table, and the ratios for the time points were calculated against the 0 h value.
CSF cerebrospinal fluid, TMT tandem mass tag
Fig. 1 Study design. CSF sampled at several time points following
oral administration of semagacestat was subjected to labeling using
TMT reagents 128-131. The combined labeled samples from each
participant (TMT 6-plex set) were centrifuged through a 30 kDa
molecular weight cut-off filter. The flow-through, containing the
endogenous peptide fraction, was analyzed by LC-MS. The relative
change in concentration of each identified peptide was calculated
from the TMT reporter ion signals. CSF cerebrospinal fluid, TMT tandem
mass tag, LC-MS liquid chromatography-mass spectrometry
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Liquid chromatography-mass spectrometry
Endogenous peptides were reconstituted in 12 μl of 2 %
acetonitrile, 0.1 % trifluoroacetic acid. A sample of 6 μl
was analyzed with nano-LC (Ultimate 3000, Thermo Sci-
entific) with a C18 trap column, and a C18 separation
column, coupled to a Q-Exactive electrospray ionization
mass spectrometer (Thermo Scientific). The LC mobile
phases were A: 0.05 % formic acid, and B: 84 % aceto-
nitrile, 0.05 % formic acid. The samples were separated
with a 160 minute gradient running from 3 % mobile
phase B to 45 % mobile phase B. The mass spectrometer
was operated in the positive ion mode. The instrument
settings for the MS scans were: resolution 70,000; m/z
range 400-1600; max injection time 250 ms; AGC target
1e6. Data-dependent acquisition was used to record up
to 10 consecutive fragment ion spectra (MS2) per full
scan spectrum, selecting precursor ions in decreasing
order of intensity, and using 20 s dynamic exclusion,
and charge state exclusion to exclude signals with un-
assigned charge, charge 1 and >5. The isolation window
was set to 1.2m/z. The instrument settings for the MS2
scans were: resolution 35,000 for endogenous peptides
and 17,500 for tryptic peptides; fixed first mass m/z 100;
max injection time 120 ms for endogenous peptides and
60 ms for tryptic peptides; AGC target 1e5. Blank injec-
tions of mobile phase B were performed between the
samples to avoid carry-over.
Data analysis
The data from the two replicate runs of each participant
were used in a MudPIT search using the software Proteome
Discoverer 1.4 (Thermo Scientific). Protein identification
was performed using Mascot v. 2.3 (Matrix Sciences, UK),
searching the human subset of the UniProtKB/Swiss-Prot
database (Release 2013-10, 88,266 sequences). The en-
dogenous peptides were searched with the following
settings: fixed modifications: TMT 6-plex modification
of peptide N-termini and lysines, and carbamidometh-
ylation of cysteines; variable modification: oxidation of
methionine. The mass error tolerance was set to 10 ppm
in MS mode and 20 milli-mass units in MS/MS mode.
The peptide cut-off score for individual spectra was 10. A
target false discovery rate value of 5 %, based on decoy
database searches, was used as identification criterion.
The quantification was done on the MS/MS level where
reporter ions from the TMT 6-plex reagents were used for
relative quantification. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Con-
sortium [20] via the PRIDE partner repository with the
dataset identifier PXD003075 and 10.6019/PXD003075".
The CSF sample collected at time point 0 h was used
as reference sample for each individual and the change
in peptide abundance at later time points was calculated
relative to the peptide’s abundance at this time point.
A majority of the identified endogenous peptides in-
creased between each time point regardless of whether
the participant received placebo or the active substance.
This has been observed for other analytes measured in
these samples [9, 19]. The average increase over 24 h
was 47 %. This drift was normalized toward baseline by
subtracting the median ratio of the placebo group from
the two groups that received the active substance for
each peptide and time point.
The data were evaluated according to the following
criteria: 1) the alterations of the peptide levels should
be dose dependent; 2) the levels should not fluctuate
Table 2 Peptides affected by drug treatment
Peptide Protein p Time at maximum
decrease (h)
% maximum
decrease140 mg 280 mg
EDVGSNK Amyloid Precursor Protein and
Amyloid beta A4 proteinab
0.36 0.0035 9 42
DELAPAGTGVSREAVSG Amyloid-like protein 1ab 0.077 0.0018 12 32
SVQPDSPTDVNQENVPS Tachykinin-3 0.065 0.0041 9 38
VTEDDEDEDDDKE Testican-1 0.25 0.0039 18 26
AVTEDDEDE Testican-1 0.065 0.0025 18 19
DDEDEDDDKE Testican-1 0.41 0.0039 18 26
EKLPGQGVHSQGQGPGAN Golgi apparatus protein 1a 0.11 0.0020 18 20
DFLAEGGGVR Fibrinogen alpha chain 0.66 0.0024 9 36
EPPPPPEPA CD99 antigen-like protein 2a 0.69 0.0041 18 24
TVVQPSVGAAAGPVVPPCPGRIRHFKV Alpha-2-HS-glycoprotein 0.86 0.0039 9 27
DPNCSCATGGSCTCAGSCKCKE Metallothionein-1E - 0.0050 12 42
Endogenous CSF peptides that decreased in abundance after treatment with semagacestat
CSF cerebrospinal fluid
atransmembrane protein
bpreviously reported gamma secretase substrate
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substantially between each time point; 3) spikes at isolated
time points were not considered to be drug dependent; 4)
values from at least four individuals in each group were
required to be present; and 5) the peptide levels should
return toward the placebo groups’ values at 36 h. Be-
cause peptide abundances cannot be assumed to be
normally distributed, the non-parametric Friedman test
in the software PASW Statistics 18 (IBM) was used to
evaluate the remaining peptides, employing a significance
threshold of p < 0.05.
Results
The aim of the current study was to test if an unbiased
endopeptidomic approach could be used to detect changes
in the CSF endopeptidome in response to drug treatment.
In total, 1798 endogenous peptides were identified and
quantified in at least one TMT 6-plex set (corresponding
to one individual). Of these, 302 endogenous peptides
fulfilled the set quantification criteria of being identified
and quantified in at least four participants in each of the
three treatment groups (Additional file 1: Table S1). Of
these, 11 peptides were significantly affected (p < 0.05) by
treatment with semagacestat (Table 2).
One of these was the peptide EDVGSNK, constituting
fragment 22-28 of Aβ (Fig. 2). Within the SwissProt se-
quence database, this peptide sequence is unique to
APP. As the GSI blocks production of Aβ by inhibit-
ing c-terminal cleavage from APP, decreased
EDVGSNK indicates that the drug hits the target and
affects Aβ production. The abundance of the peptide
decreased by a maximum of 42 % after 9 h in the group
that received 280 mg of semagacestat (p = 0.0035) (Fig. 2b).
A 13 % decrease was observed in the group that received
140 mg.
Another peptide that changed in abundance was
DELAPAGTGVSREAVSG (Fig. 3). The peptide is a
Fig. 2 β-amyloid 22-28. The peptide EDVGSNK, constituting fragment 22-28 of β-amyloid within APP. a annotated MS2 spectrum. b Relative abundance of
the peptide after semagacestat treatment. In the 280 mg dosage group the concentration of the peptide decreased to a minimum of 42 % at
9 h (p = 0.0035), while in the 140 mg dosage group the minimum relative abundance was 13 % at 12 h (p = 0.36). Graphed data are medians
with median absolute deviations. APP amyloid precursor protein
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fragment of amyloid-like protein 1 (APLP1), also
known to be cleaved by γ-secretase [21]. The peptide,
denoted APLP1β17, decreased by a maximum of 32 %
after 12 h in the group that received 240 mg (Fig. 3b).
Of the remaining peptides, two were derived from
proteins with transmembrane regions (Golgi apparatus
protein 1 and CD99 antigen-like protein 2), which are
thus potential gamma γ-secretase substrates.
Discussion
While human CSF has been found to contain a large
number of endogenous peptides, relatively little research
has been performed to explore the potential of this class
of molecules as a source of biomarkers. The current
study is, to our knowledge, the first in which an explora-
tive endopeptidomic approach has been employed to
identify drug treatment biomarkers in CSF. Of 303 en-
dogenous peptides that could be reproducibly identified
in at least 50 % of the study participants, 11 differed sig-
nificantly in abundance compared to t0, at one or several
time points, and of these, two were derived from known
gamma secretase substrates, which thus would be expected
to be affected by the treatment. These proportions support
our hypothesis that an unbiased peptidomic approach is
Fig. 3 APL1β17. The peptide DELAPAGTGVSREAVSG, constituting fragment APL1β17 from amyloid-like protein 1 (APLP1). a Annotated MS2 spectrum.
b Relative abundance of the peptide after semagacestat treatment. In the 280 mg dosage group the concentration of the peptide decreased
to a minimum of 32 % at 12 h (p = 0.0018), and in the 140 mg group the minimum relative concentration was 15 % at 18 h (p = 0.078). Graphed data
are medians with median absolute deviations
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sufficiently specific to detect treatment-induced changes on
the peptide level.
While Aβ22-28, which decreased upon semagacestat
treatment (Fig. 2), has not been previously identified
in CSF, previous studies reported decreased levels of
Aβx-38, Aβx-40, and Aβx-42 in CSF after a single dose
[19] and a decrease in the production of total Aβ in a
dose dependent fashion [9]. The γ-secretase protease
complex acts within the cellular membrane and cleaves its
substrate proteins within their transmembrane-spanning
region. Although position 28 in the Aβ sequence is at the
edge of the transmembrane region (Fig. 4a), it has not
been reported as a γ-secretase cleavage site. Through mass
spectrometry-based studies we have learned that several
different Aβ peptides are present in the CSF and that they
are affected differently by treatment [22]. For example, we
have previously shown, using immunoprecipitation in
combination with MS, that chronic treatment of AD par-
ticipants with semagacestat results in increased levels of
Aβ1-15 and Aβ1-16 [23]. Even though these short Aβ
peptides are not generated directly by γ-secretase cleavage,
inhibition of γ-secretase may induce an accumulation of
C99, the transmembrane carboxyl-terminal domain of
APP, which in turn is cleaved by α- and β-secretases
resulting in increased levels of Aβ1-15 and Aβ1-16 [24].
Thus, the observed decrease in Aβ22-28 does not neces-
sarily imply that γ-secretase cleaves at position 28 but may
instead reflect decreased production of a longer Aβ
peptide, which is then further cleaved by other proteases
to Aβ22-28.
That full-length Aβ40 or Aβ42 was not detected is a
limitation of this study, resulting from steps in the
sample preparation and analytical conditions: C18
chromatographic media, used in LC-MS, may interact
too strongly with the highly hydrophobic longer Aβ
peptides, preventing their elution. Furthermore, following
lyophilization, the samples were reconstituted in acidified
aqueous solution, in which the solubility of the longer Aβ
peptides is low. Using a complementary sample prepar-
ation, for example employing basic solvents, and C4 or
C8 chromatographic media, may provide a more
complete view on the processed peptides.
APL1β17, a 17-amino acid long peptide located near
the transmembrane region of APLP1 (Fig. 4b), also de-
creased in response to the treatment (Fig. 3). The peptide
showed a maximum decrease 12 h after drug intake,
which matches observations of truncated Aβ peptides
after treatment with semagacestat [19]. Like APP, APLP1
also is a known substrate for γ-secretase [21]. It is proc-
essed around the transmembrane region by the same en-
zymes as APP, resulting in the formation of Aβ-like
peptides [21, 25]. Specifically, APLP1β25, APLP1β27, and
APLP1β28 from APLP1 have been shown to be generated
by β - and γ-secretase cleavage [25]. These peptides have,
however, not been found to be a part of amyloid plaques
[25], in contrast to full length APLP1 [26].
The overall levels of endogenous peptides increased
over time in all groups; this has also been observed in a
previous study of the same CSF samples [19]. The increase
may be caused by changes in the cephalic to caudal
gradient when sampling CSF repeatedly over 36 hours.
Therefore, in the current study, the increase was cor-
rected for each endogenous peptide by subtracting the
median value of the placebo group from the median value
of the treatment groups.
The majority of the identified peptides that were af-
fected by semagacestat treatment were not previously
known γ-secretase substrates. Notably, several of these
were derived from proteins without transmembrane do-
mains and would thus not be expected to be γ-secretase
Fig. 4 Transmembrane location of Aβ22-28 and APLP1β17. Location of the peptides (a) Aβ22-28 and (b) APLP1β17 relative to the transmembrane
region of their respective protein sequences. The γ-secretase cleavage sites in APP are indicated with arrows. APP amyloid precursor protein
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substrates. This observation may indicate a direct or in-
direct modulation of protein metabolism through inhib-
ition of γ-secretase, suggesting that GSIs may have even
broader biological effects than predicted from γ-
secretase substrates alone. The clinical trials with the
drug failed because of a number of adverse effects, most
importantly cognitive worsening, that occurred for un-
known reasons. The changes observed in many of the
endogenous peptides may not necessarily be the direct
result of γ-secretase activity, but may be caused by
downstream γ-secretase dependent processing or could
be the result of drug effects on other proteases. These
changes demonstrate the importance of analyzing the
global composition of the samples in similar studies to
elucidate whether a drug affects processes other than
those expected or gives rise to unintended alterations
among endogenous peptides or proteins. The informa-
tion obtained in these experiments might also identify
novel candidates for the enzymes whose functions are
being modified with a treatment in vivo, which otherwise
can be hard to identify/detect.
Conclusions
Among the 303 endogenous peptides identified in total,
a significant change in abundance in response to GSI
treatment was detected in 11 peptides, and among those,
two were derived from proteins that are known substrates
to γ-secretase. These results support our hypothesis that
an unbiased endopeptidomic analytical approach can be
used to detect peptides that are affected by drug treat-
ment, and suggest that this approach may be valuable to
include in future clinical trials.
Additional file
Additional file 1: Table S1. Identified peptides. Peptides identified and
quantified in at least four participants in each of the three treatment
groups. Quantitative data are presented as percent change relative to
CSF sampled at the time point when the drug was administered. The
values are normalized to the average relative peptide abundance in the
placebo group for each time point. (XLSX 86 kb)
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